Printer Friendly

LTT Bio-Pharma Wins Governmental Backing for Its Collaborative Research on Nonsteroidal Antiinflammatory Drug.

Tokyo, Japan, Aug 4, 2005 - (JCNN) - LTT Bio-Pharma, a Japanese pharmaceutical company specializing in drug delivery systems, announced on August 2 that the Japan Science and Technology Agency (JST) has selected the company's proposal as one of the projects JST supports.

Further, the company and JST signed a three-year contract on August 1. Under this contract, the company, in collaboration with Professor Tohru Mizushima at the Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, will proceed with research on next-generation nonsteroidal anti-inflammatory drugs.

Specifically, they aim to develop agents that will be free from developing gastric ulcer and myocardial infarction.

JST will provide the project with a fund of 50 million yen ($450,000) for fiscal 2005.

Source: JCN

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Aug 5, 2005
Previous Article:National Institute of Agrobiological Sciences Successfully Controls Silkworm's Metamorphosis.
Next Article:Kyorin Pharmaceutical to License Its Overactive Bladder Drug to Korean LG Life Sciences.

Related Articles
COX-2 inhibitor pulled off market.
Company pulls pain drug from market.
"Pharma & Bio Ingredients" from Rodman Publications.
I'rom, LTT Bio-Pharma to Jointly Deploy Anti-aging Business.
I'rom, LTT Bio-Pharma to Establish Joint Venture for Anti-aging Business.
LTT Bio-Pharma Announces Results of Research on Porous Hydroxyapatite Particles.
LTT Bio-Pharma and Others to Co-develop Adhesive Preparation in China.
LTT Bio-Pharma, Jikei University to Jointly Develop Innovative DDS for Steroids.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |